NCT03800121Completed
Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC)
Source: ClinicalTrials.gov · Last updated 5 Jun 2025
Brief summary (registry, in English)
Sarcomas are rare cancers with a high risk of metastatic progression and a major pejorative factor with respect to patient survival. The estimation of the metastatic risk of sarcomas is very complex given the histological heterogeneity of this entity. It is therefore essential that, at diagnosis, a reliable evaluation of this metastatic potential be made, in order to adapt the therapeutic strategy as well as possible. It has recently been discovered that sarcomas secrete many exosomes that appear to play an important role in tumorogenesis, growth, tumor progression and the onset of metastases. They contain many proteins and nucleic acids (DNA, RNA, microRNA), reflecting the characteristics of the tumor. It has been shown that the amount of exosomes can be correlated with the grade of malignancy of the tumor. Present in the blood, exosomes offer the possibility of non-invasively analyzing the molecular information of the cancer cell. As a result, the study of serum exosomes derived from sarcomas has a high potential as a liquid biopsy to evaluate cancer pathogenesis, progression, and treatment efficacy. The purpose of this study is to demonstrate in patients with sarcomas that exosomes can be used to monitor their disease and be used as a predictor of the risk of recurrence.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 34 (actual)
- First submitted
- 3 Jan 2019
- Start date
- 19 Nov 2018
- Primary completion date
- 19 Nov 2024
- Lead sponsor
- Centre Georges Francois Leclerc
- Diseases
- Sarcoma
- NCT number
- NCT03800121
What you commit to
- Study type: Observational
- Participants enrolled: 34
- From 19 Nov 2018 to the primary completion date, 19 Nov 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with a history of cancer other than sarcoma in the 5 years preceding the diagnosis of sarcoma
- Serology HIV and / or HBV and / or HCV positive.
Other
- Patients who meet at least one of the following criteria will not be eligible:
- Patient with another synchronous tumor,
- Patient with sarcoma in irradiated territory
- Patient unable to undergo medical follow-up for geographical, social or psychological reasons,
- Person benefiting from a protection system for adults (including guardianship and trusteeship),
- Pregnant or lactating woman.
- Patients unable to understand, read and / or sign informed consent.
Who the study is looking for
- Men and women newly diagnosed with localized, metastatic or locally advanced soft tissue sarcoma
- Previous treatment of the disease with chemotherapy, radiotherapy or surgery is allowed if it has been completed for more than 12 months at the time of inclusion.
- For metastatic or locally advanced (inoperable) sarcoma, patients for whom first-line metastatic chemotherapy is indicated.
- Age ≥18 years
- Affiliation to a social security scheme
- Patients who signed informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Besançon Coordinator of this site? Confirm its status | Besançon | France | Unknown status |
| Centre Georges François Leclerc Coordinator of this site? Confirm its status | Dijon | France | Unknown status |
| CHU de Poitiers Coordinator of this site? Confirm its status | Poitiers | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.